Why the study?
Does an unconventional TEER strategy improve clinical outcomes in a high-risk patient with massive primary mitral regurgitation who is ineligible for standard TEER according to guidelines?
Does an unconventional TEER strategy improve clinical outcomes in a high-risk patient with massive primary mitral regurgitation who is ineligible for standard TEER according to guidelines?
TEER may serve as a viable last-resort treatment for high-risk patients with massive primary mitral regurgitation who fall outside current guideline recommendations.
Answers are grounded in this paper and cite their sources.
May support unconventional TEER as last-resort in guideline-ineligible massive primary MR; leaves open prospective validation in high-risk cohorts.
A 58-year-old male with prior history of mechanical aortic valve replacement (AVR) in 2009 for severe symptomatic aortic regurgitation in a bicuspid aortic valve, and since 2013 a new-onset severe asymptomatic primary mitral regurgitation (MR) due to prolapse of the anterior mitral valve leaflet (AMVL) presented himself with acute heart failure. Based on current guidelines recommendations, this patient was not eligible for transcutaneous mitral valve edge-to-edge repair (TEER), as well he was found as too high risk for conventional mitral valve repair. However, as a last resort TEER was undertaken with an unconventional strategy, which resulted in resolution of the MR and improvement of clinical, biochemical findings.
No takes yet. Share an insight, caveat, or question.
Eerdekens et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: